A TCR mimic CAR T cell specific for NDC80 is broadly reactive with solid tumors and hematologic malignancies
MG Klatt, T Dao, Z Yang, J Liu, SS Mun… - Blood, The Journal …, 2022 - ashpublications.org
Target identification for chimeric antigen receptor (CAR) T-cell therapies remains
challenging due to the limited repertoire of tumor-specific surface proteins. Intracellular …
challenging due to the limited repertoire of tumor-specific surface proteins. Intracellular …
Low-dose CDK4/6 inhibitors induce presentation of pathway specific MHC ligands as potential targets for cancer immunotherapy
ABSTRACT Cyclin dependent kinase 4/6 inhibitors (CDK4/6i) lead to cell-cycle arrest but
also trigger T cell-mediated immunity, which might be mediated by changes in human …
also trigger T cell-mediated immunity, which might be mediated by changes in human …
Improving the Efficacy and Repertoire of Cancer Immunotherapy with Rational Small-Molecule Combinations
CM Bourne - 2023 - search.proquest.com
Cancer immunotherapy harnesses the immune system to kill cancer. Antibody and adoptive
T cell therapies target specific antigens expressed on cancers. Antibodies bind extracellular …
T cell therapies target specific antigens expressed on cancers. Antibodies bind extracellular …